Showing results (131-140 of 248) with videos related to

Sort By:
Pageof 25
Hematological Oncology|October 20, 2022
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohortMichele Merli, Isacco Ferrarini, Francesco Merli, et al.
Hemasphere|April 10, 2023
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana LinfomiManuel Gotti, Roberta Sciarra, Alessandro Pulsoni, et al.
Hematological Oncology|April 10, 2016
Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphomaManuel Gotti, Marta Nicola, Marco Lucioni, et al.
Hematological Oncology|June 4, 2014
PBSC mobilization in lymphoma patients: analysis of risk factors for collection failure and development of a predictive score based on the kinetics of circulating CD34+ cells and WBC after chemotherapy and G-CSF mobilizationGiuseppe Rossi, Cristina Skert, Enrico Morello, et al.
Autoimmunity Reviews|March 14, 2017
International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statementAnna Linda Zignego, Manuel Ramos-Casals, Clodoveo Ferri, et al.
Blood|January 29, 2013
Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasmsMarzia Varettoni, Luca Arcaini, Silvia Zibellini, et al.
British Journal of Haematology|December 2, 2017
Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphomaLuca Arcaini, Thierry Lamy, Jan Walewski, et al.
Blood|October 21, 2018
Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapyShigeru Kusumoto, Luca Arcaini, Xiaonan Hong, et al.
British Journal of Haematology|July 6, 2019
A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disordersMarzia Varettoni, Silvia Zibellini, Emanuela Boveri, et al.
British Journal of Haematology|January 20, 2007
Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare diseaseLuca Arcaini, Marco Paulli, Sara Burcheri, et al.
Pageof 25